Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

EMA accepts for review MAA for dupilumab in atopic dermatitis

Dec. 9, 2016

Dosing begins in phase III program of ReVance Therapeutics' daxibotulinumtoxinA

Dec. 9, 2016

Aclaris Therapeutics clear to begin phase I testing of ATI-50001

Dec. 9, 2016

AmorePacific initiates phase III trial of PAC-14028 in atopic dermatitis

Dec. 2, 2016

Novan reports topline results from phase II study of SB-206

Nov. 30, 2016

PRMT5 inhibitors could represent new therapeutic approach in treatment of psoriatic diseases

Nov. 29, 2016

Janssen-Cilag seeks approval of guselkumab in Europe

Nov. 25, 2016

SM-04755 demonstrates promise in models of psoriasis, chronic tendinopathy and scleroderma

Nov. 24, 2016

Eli Lilly Japan and Torii Pharmaceutical launch Taltz in Japan

Nov. 23, 2016

Novan reports promising preclinical data on SB-414 for psoriasis

Nov. 18, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...